MUC4 is increased in high grade intraepithelial neoplasia in Barrett's oesophagus and is associated with a proapoptotic Bax to Bcl-2 ratio

被引:23
作者
Bax, DA
Haringsma, J
Einerhand, AWC
van Dekken, H
Blok, P
Siersema, PD
Kuipers, EJ
Kusters, JG
机构
[1] Univ Med Ctr Rotterdam, Erasmus MC, Dept Gastroenterol & Hepatol, NL-3015 GD Rotterdam, Netherlands
[2] Sophia Childrens Univ Hosp, Erasmus MC, Lab Paediat, Rotterdam, Netherlands
[3] Univ Med Ctr, Erasmus MC, Dept Pathol, Rotterdam, Netherlands
[4] Leyenburg Ziekenhuis, Dept Pathol, The Hague, Netherlands
关键词
D O I
10.1136/jcp.2004.017020
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Background: Patients with Barrett's oesophagus (BO) are at risk of oesophageal adenocarcinoma. Because the pattern of mucosal mucins changes during neoplastic progression, it may serve as a marker of intraepithelial neoplasia. Aims: To determine the expression pattern of mucins in neoplastic BO epithelium ( high grade dysplasia) and correlate it with the expression of apoptosis markers Bax and Bcl-2. Methods: Thirty seven patients with BO were studied: 16 without intraepithelial neoplasia, six with high grade intraepithelial neoplasia (HGN), and 15 with infiltrating adenocarcinoma. Biopsies were obtained from squamous epithelium, Barrett's epithelium, and ( when present) foci of suspected HGN or adenocarcinoma. MUC1-4, MUC5AC, MUC5B, MUC6, Bax, and Bcl-2 mRNA were determined by semiquantitative RT-PCR. MUC2, MUC5AC, and MUC6 protein was determined by immunoblotting. Results: Mucin expression varied between neoplastic progression stages in BO. Mucin mRNA levels were low in squamous epithelium, except for MUC4, and were at least four times higher in BO and HGN (p< 0.001), but less so in adenocarcinoma. MUC4 expression was significantly lower in BO than in normal squamous epithelium, whereas in HGN and adenocarcinoma, levels were significantly higher than in BO ( p = 0.037). The Bax: Bcl-2 ratio was increased in HGN compared with BO ( p = 0.04). MUC2, MUC5AC, and MUC6 protein values correlated with mRNA data. Conclusions: Mucin expression varies during the development of oesophageal adenocarcinoma in BO. MUC4 could serve as a tumour marker in this process. In contrast to animal studies, upregulation of MUC4 in HGN is associated with increased apoptosis, suggesting that MUC4 plays a minor role in apoptosis regulation in BO.
引用
收藏
页码:1267 / 1272
页数:6
相关论文
共 39 条
  • [21] Muc4/sialomucin complex, an intramembrane modulator of ErbB2/HER2/Neu, potentiates primary tumor growth and suppresses apoptosis in a xenotransplanted tumor
    Komatsu, M
    Jepson, S
    Arango, ME
    Carraway, CAC
    Carraway, KL
    [J]. ONCOGENE, 2001, 20 (04) : 461 - 470
  • [22] Komatsu M, 1999, CANCER RES, V59, P2229
  • [23] Komatsu M, 2000, INT J CANCER, V87, P480, DOI 10.1002/1097-0215(20000815)87:4<480::AID-IJC4>3.0.CO
  • [24] 2-6
  • [25] Differential expression of mucins and trefoil peptides in native epithelium, Barrett's metaplasia and squamous cell carcinoma of the oesophagus
    Labouvie, C
    Machado, JC
    Carneiro, F
    Sarbia, M
    Vieth, M
    Porschen, R
    Seitz, G
    Blin, N
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1999, 125 (02) : 71 - 76
  • [26] Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma
    Lagergren, J
    Bergström, R
    Lindgren, A
    Nyrén, O
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (11) : 825 - 831
  • [27] MUC4 expression is increased in dysplastic cervical disorders
    López-Ferrer, A
    Alameda, F
    Barranco, C
    Garrido, M
    De Bolós, C
    [J]. HUMAN PATHOLOGY, 2001, 32 (11) : 1197 - 1202
  • [28] Transcriptional regulation of human mucin MUC4 by bile acids in oesophageal cancer cells is promoter-dependent and involves activation of the phosphatidylinositol 3-kinase signalling pathway
    Mariette, C
    Perrais, M
    Leteurtre, E
    Jonckheere, N
    Hémon, B
    Pigny, P
    Batra, S
    Aubert, JP
    Triboulet, JP
    Van Seuningen, I
    [J]. BIOCHEMICAL JOURNAL, 2004, 377 : 701 - 708
  • [29] Miwa K, 1996, INT J CANCER, V67, P269, DOI 10.1002/(SICI)1097-0215(19960717)67:2<269::AID-IJC19>3.0.CO
  • [30] 2-6